GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Fennec Pharmaceuticals Inc (STU:RV41) » Definitions » Cyclically Adjusted Price-to-FCF

Fennec Pharmaceuticals (STU:RV41) Cyclically Adjusted Price-to-FCF : (As of May. 28, 2024)


View and export this data going back to . Start your Free Trial

What is Fennec Pharmaceuticals Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Fennec Pharmaceuticals Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Fennec Pharmaceuticals's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fennec Pharmaceuticals Cyclically Adjusted Price-to-FCF Chart

Fennec Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Fennec Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Fennec Pharmaceuticals's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Fennec Pharmaceuticals's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Fennec Pharmaceuticals's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Fennec Pharmaceuticals's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Fennec Pharmaceuticals's Cyclically Adjusted Price-to-FCF falls into.



Fennec Pharmaceuticals Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Fennec Pharmaceuticals's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Fennec Pharmaceuticals's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=1.155/131.7762*131.7762
=1.155

Current CPI (Mar. 2024) = 131.7762.

Fennec Pharmaceuticals Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 -0.031 100.560 -0.041
201409 -0.031 100.428 -0.041
201412 -0.038 99.070 -0.051
201503 -0.033 99.621 -0.044
201506 -0.042 100.684 -0.055
201509 -0.042 100.392 -0.055
201512 -0.036 99.792 -0.048
201603 -0.041 100.470 -0.054
201606 -0.033 101.688 -0.043
201609 -0.036 101.861 -0.047
201612 -0.042 101.863 -0.054
201703 -0.046 102.862 -0.059
201706 -0.043 103.349 -0.055
201709 -0.051 104.136 -0.065
201712 -0.068 104.011 -0.086
201803 -0.076 105.290 -0.095
201806 -0.072 106.317 -0.089
201809 -0.072 106.507 -0.089
201812 -0.130 105.998 -0.162
201903 -0.110 107.251 -0.135
201906 -0.123 108.070 -0.150
201909 -0.102 108.329 -0.124
201912 -0.072 108.420 -0.088
202003 -0.171 108.902 -0.207
202006 -0.118 108.767 -0.143
202009 -0.181 109.815 -0.217
202012 -0.104 109.897 -0.125
202103 -0.116 111.754 -0.137
202106 -0.141 114.631 -0.162
202109 -0.097 115.734 -0.110
202112 -0.110 117.630 -0.123
202203 -0.100 121.301 -0.109
202206 -0.123 125.017 -0.130
202209 -0.194 125.227 -0.204
202212 -0.240 125.222 -0.253
202303 -0.196 127.348 -0.203
202306 -0.138 128.729 -0.141
202309 -0.097 129.860 -0.098
202312 -0.167 129.419 -0.170
202403 1.155 131.776 1.155

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Fennec Pharmaceuticals  (STU:RV41) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Fennec Pharmaceuticals Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Fennec Pharmaceuticals's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Fennec Pharmaceuticals (STU:RV41) Business Description

Traded in Other Exchanges
Address
68 TW Alexander Drive, PO Box 13628, Research Triangle Park, NC, USA, 27709
Fennec Pharmaceuticals Inc is a clinical-stage biotechnology company. It is engaged in research and development activities. The company is developing Sodium Thiosulfate (STS), a chemo-protectant against hearing loss associated with platinum-based chemotherapy. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin induced hearing loss, or ototoxicity in children. The company principally operates in the United States.

Fennec Pharmaceuticals (STU:RV41) Headlines

No Headlines